Results 121 to 130 of about 2,580,445 (341)

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Energy-efficient Resource Allocation in Multi-Tenant Edge Computing using Markov Decision Processes

, 2022
Alessandro Spallina, Andrea Araldo, Tijani Chahed, Hind Castel-Taleb, Antonella Di Stefano, Tülin Atmaca   +5 more
openalex   +2 more sources

Feasibility study of an Integrated Program for Aerospace vehicle Design (IPAD). Volume 2: The design process [PDF]

The extent to which IPAD is to support the design process is identified. Case studies of representative aerospace products were developed as models to characterize the design process and to provide design requirements for the IPAD computing ...
Gillette, W. B., Kowalik, J. S., Southall, J. W., Turner, M. J., Whitener, P. C.   +4 more
core   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Towards a universal framework for heat pump monitoring at scale

Buildings & Cities
As heat pump installation across Europe increases, monitoring system performance on a large scale is key for policy decisions and customer confidence. However, in-situ heat pump monitoring has been found in previous work to be very challenging.
Jenny Crawley, Leon Domoney, Adam O’Donovan, Jez Wingfield, Cristian Dinu, Oliver Kinnane, Paul O’Sullivan   +6 more
doaj   +1 more source

An Introduction to the Process of Quantum Computing

, 2022
Neetu Neetu
openalex   +1 more source

The Ultimate DataFlow for Ultimate SuperComputers-on-a-Chip, for Scientific Computing, Geo Physics, Complex Mathematics, and Information Processing [PDF]

, 2021
Veljko Milutinović, Erfan Sadeqi Azer, Kristy Yoshimoto, Gerhard Klimeck, Miljan Djordjevic, Miloš Kotlar, M. Bojović, Bozidar Miladinovic, Nenad Korolija, Stevan Stanković, Nenad Filipović, Zoran Babović, Miroslav Kosanić, Akira Tsuda, Mateo Valero, Massimo De Santo, Erich Neuhold, Jelena Skoručak, Laura Dipietro, Ivan Ratković   +19 more
openalex   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

A cyber process control system based on pattern recognition and cloud computing

, 2022
Amr Mohamed Ali, Soumaya Yacout, El-Adl Rabeih, Yasser Shaban   +3 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source